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Abstract Imbalances in endoplasmic reticulum (ER) proteostasis are associated with
etiologically-diverse degenerative diseases linked to excessive extracellular protein misfolding and
aggregation. Reprogramming of the ER proteostasis environment through genetic activation of the
Unfolded Protein Response (UPR)-associated transcription factor ATF6 attenuates secretion and
extracellular aggregation of amyloidogenic proteins. Here, we employed a screening approach that
included complementary arm-specific UPR reporters and medium-throughput transcriptional
profiling to identify non-toxic small molecules that phenocopy the ATF6-mediated reprogramming
of the ER proteostasis environment. The ER reprogramming afforded by our molecules requires
activation of endogenous ATF6 and occurs independent of global ER stress. Furthermore, our
molecules phenocopy the ability of genetic ATF6 activation to selectively reduce secretion and
extracellular aggregation of amyloidogenic proteins. These results show that small molecule-
dependent ER reprogramming, achieved through preferential activation of the ATF6 transcriptional
program, is a promising strategy to ameliorate imbalances in ER function associated with
degenerative protein aggregation diseases.
DOI: 10.7554/eLife.15550.001
Introduction
Nearly 1/3 of the human proteome is targeted to the endoplasmic reticulum (ER) for folding and
trafficking to downstream secretory pathway environments, including the extracellular space. These
secreted proteins engage ER-localized protein homeostasis (or proteostasis) factors such as chaper-
ones and folding enzymes to facilitate their folding (Brodsky and Skach, 2011; Powers et al.,
2009). Proteins unable to fold in the ER are identified by ER proteostasis factors that direct them
towards the proteasome (via ER-associated degradation) or lysosome for degradation (Brodsky and
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Skach, 2011; Smith et al., 2011). This partitioning toward degradation pathways prevents the fold-
ing and trafficking of destabilized, misfolding-prone proteins from the ER, which could aggregate
into proteotoxic conformations in downstream secretory environments (Brodsky and Skach, 2011;
Chen et al., 2011; Powers et al., 2009).
Many degenerative diseases result from imbalances in ER proteostasis (Hipp et al., 2014;
Luheshi et al., 2008). The aberrant secretion of properly folded, but destabilized aggregation-prone
proteins facilitates extracellular proteotoxic aggregation associated with many amyloid diseases
(Tipping et al., 2015). Examples include the transthyretin (TTR) or light chain (AL) amyloidoses (Blan-
cas-Mejia and Ramirez-Alvarado, 2013). Similarly, the inability to efficiently degrade destabilized,
aggregation-prone variants of secreted proteins such as rhodopsin and a-1-antitrypsin (A1AT) facili-
tates their proteotoxic intracellular aggregation, linked to retinitis pigmentosa and liver disease,
respectively (Gooptu et al., 2014; Lin and Lavail, 2010).
One strategy to ameliorate the above-mentioned and related diseases is to transcriptionally
reprogram the ER proteostasis network (ER PN), which has the potential to increase the ER’s capac-
ity to identify destabilized, misfolding-prone proteins and prevent their secretion to downstream
secretory environments (Calamini and Morimoto, 2012; Chen et al., 2015; Gestwicki and Garza,
2012). ER PN remodeling can be achieved by activation of the unfolded protein response (UPR),
comprising three signaling pathways activated downstream of the ER stress sensing proteins IRE1,
ATF6, and PERK (Walter and Ron, 2011). In response to the accumulation of misfolded proteins
within the ER (i.e., ER stress), these sensors are activated, resulting in ER PN reprogramming pre-
dominantly mediated by the UPR-associated transcription factors XBP1s and ATF6. These transcrip-
tion factors induce distinct, but overlapping, transcriptional programs that alter the composition of
ER PN pathways (Adachi et al., 2008; Shoulders et al., 2013; Yamamoto et al., 2004). Intriguingly,
preferential ATF6-mediated reprogramming of the ER PN offers a unique opportunity to alter the
eLife digest Newly made proteins must be folded into specific three-dimensional shapes before
they can perform their roles in cells. Many proteins are folded in a compartment called the
endoplasmic reticulum before being transported to their final location. However, if a cell suddenly
needs to make a large number of new proteins, it can overwhelm the endoplasmic reticulum and
unfolded proteins may accumulate. The cell responds to this stress by activating the unfolded
protein response, which increases the folding capacity of the endoplasmic reticulum to match the
demand. However, if the stress persists, then the unfolded protein response instructs the cell to die
to protect the rest of the body.
A protein called ATF6 is involved in one branch of the unfolded protein response. Endoplasmic
reticulum stress causes ATF6 to move from the endoplasmic reticulum to another cell compartment
where certain enzymes are able to cut the protein. A fragment of ATF6 then moves to the nucleus of
the cell to activate genes needed to increase the cell’s capacity to fold proteins.
Errors in protein folding can cause serious diseases in humans and other animals. Drugs that
target ATF6 might be able to regulate part of the unfolded protein response to treat these diseases.
However, no drugs that act on ATF6 had been identified. Now, two groups of researchers have
independently identified small molecules that specifically target ATF6.
Plate et al. used a new approach to screen over 600,000 small molecules and identified a small
number that could activate ATF6-regulated genes without inducing global endoplasmic reticulum
stress. Further experiments tested whether any of these ATF6 drug candidates could prevent the
release of incorrectly folded versions of two particular proteins from cells that are associated with
types of amyloid disease in humans. One of the small molecules tested effectively reduced the
release of these proteins and prevented harmful deposits of the proteins forming in the spaces
surrounding cells.
In an independent study, Gallagher et al. identified a type of small molecule that can inhibit the
activity of ATF6. Together, these findings may lead to further development of new drugs for treating
diseases associated with incorrect protein folding in the endoplasmic reticulum.
DOI: 10.7554/eLife.15550.002
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fate of disease-associated proteins. Genetic activation of the ATF6 transcriptional program attenu-
ates intracellular accumulation of mutant rhodopsin and the Z-variant of A1AT (Chiang et al., 2012;
Smith et al., 2011). Furthermore, stress-independent chemical genetic activation of a ligand-regu-
lated ATF6 attenuates the secretion and extracellular aggregation of destabilized, amyloidogenic
variants of TTR or immunoglobulin light chains (LCs), without significantly impacting secretion of sta-
ble, non-amyloidogenic variants of these proteins or the global endogenous secreted proteome
(Chen et al., 2014; Cooley et al., 2014; Shoulders et al., 2013). These results suggest that small
molecules that similarly induce preferential ER PN remodeling through pharmacologic activation of
the ATF6 transcriptional program should attenuate the aberrant secretion and aggregation of these
proteins linked to degenerative diseases (Chen et al., 2015).
Traditionally, UPR signaling is activated using small molecule ER stressors such as the SERCA
inhibitor thapsigargin (Tg) or tunicamycin (Tm), an inhibitor of N-linked glycosylation (Chen et al.,
2015). However, chronic addition of these ER stressors induces apoptosis, predominantly through
activation of the PERK arm of the UPR (Hetz, 2012; Tabas and Ron, 2011). Small molecule kinase
inhibitors and ATP mimetics have been shown to activate the IRE1/XBP1s arm of the UPR
(Mendez et al., 2015; Papa et al., 2003; Wang et al., 2012). The small molecule BIX induces
expression of the ATF6-target gene BiP through an ATF6-dependent mechanism, but does not sig-
nificantly induce expression of other ATF6 target genes such as GRP94, p58IPK and PDIA4, likely lim-
iting its utility for ER PN reprogramming in the above-mentioned diseases (Kudo et al., 2008).
These results highlight the need for further development of molecules that preferentially activate
UPR-associated transcriptional programs, such as that regulated by ATF6, to define the benefit of
ER PN reprogramming to ameliorate protein aggregation diseases.
A challenge in identifying such compounds is the difficulty associated with efficiently assessing
the preferential activation of a sub-transcriptional pathway that is part of a highly integrated signal-
ing network (e.g., the ATF6 arm of the UPR). An increasing proportion of failed clinical trials have
highlighted the importance of the early elimination of compounds functioning through off-target
effects, which can be achieved using multidimensional assays such as gene expression profiling
(Feng et al., 2009; Verbist et al., 2015). The use of a transcriptional profiling approach early in the
drug discovery process and before functional assessment allows for the identification of promising
small molecules that preferentially activate a target transcriptional program, instead of global net-
work activation. However this strategy has only been employed in a small number of drug develop-
ment programs and has not been used to identify small molecule activators of a sub-UPR
transcriptional program, such as that regulated by ATF6 (Antipova et al., 2008; Stegmaier et al.,
2004; Stegmaier et al., 2007).
Here, we employ a cell-based high-throughput screen (HTS) in combination with transcriptional
profiling to identify non-toxic small molecules that preferentially activate the ATF6 transcriptional
program, independent of global UPR activation. Small molecule ER proteostasis regulators identified
by our screening strategy mimic the ER PN reprogramming afforded by chemical genetic ATF6 acti-
vation, through a process dependent on endogenous ATF6. Furthermore, our small molecule ER
proteostasis regulators phenocopy the ability of chemical genetic ATF6 activation to preferentially
decrease the secretion and proteotoxic aggregation of destabilized, amyloidogenic proteins without
affecting the secretion of stable, non-amyloidogenic proteins or the global endogenous secreted
proteome. These results highlight the utility of transcriptional profiling upstream of functional studies
as part of a multi-tiered screening strategy to identify small molecule ER proteostasis regulators that
can be employed to ameliorate imbalances in ER function involved in aggregation-associated degen-
erative diseases.
Results
Cell-based high-throughput screen to identify small molecule ER
proteostasis regulators
We employed a three-tiered screening strategy to identify small molecules that preferentially acti-
vate the ATF6 UPR transcriptional program for ER PN reprogramming (Figure 1A). First, a cell-based
HTS was performed using a transcriptional reporter that includes a fragment of the UPR-inducible
BiP promoter driving expression of firefly luciferase (ERSE-FLuc; Figure 1B) (Yoshida et al., 1998).
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BiP is preferentially induced by ATF6 (Shoulders et al., 2013), indicating that the ERSE-FLuc
reporter should preferentially report on activation of the ATF6 transcriptional program. We tested
the dependence of ERSE-FLuc activation on XBP1s and ATF6 in HEK293DAX cells that stably express
tet-inducible XBP1s and a trimethoprim (TMP)-regulated dihydrofolate reductase (DHFR)-ATF6
fusion, hereafter referred to as chemical genetic ATF6 activation (Shoulders et al., 2013). As pre-
dicted, the ERSE-FLuc reporter was preferentially activated by ATF6, relative to XBP1s (Figure 1—
figure supplement 1A) in HEK293DAX cells. We then stably transfected the ERSE-FLuc reporter into
Figure 1. High-throughput screen to identify small molecule ER proteostasis regulators (A) Illustration showing the
three-tiered screening strategy implemented to identify small molecules that preferentially activate the ATF6
transcriptional program. (B) Schematic of the ERSE-firefly luciferase (FLuc) reporter used in our HTS approach. (C)
Activation of FLuc luminescence in HEK293T-Rex cells stably expressing ERSE-FLuc treated with the indicated
concentration of thapsigargin (Tg) for 18 hr. Error bars represent standard deviation for n = 3 replicates. (D)
Activation of FLuc luminescence in HEK293T-Rex cells stably expressing ERSE-FLuc treated with the indicated
concentration of tunicamycin (Tm) for 18 hr. Error bars represent standard deviation for n = 3 replicates. (E) Plot
showing ERSE-FLuc activation in HEK293T-Rex cells stably expressing ERSE-FLuc treated with the 13,748 small
molecule ER proteostasis activators identified in the primary screen (6.8 mM; 18 hr). Luminescence is shown as%
signal relative to Tg treatment (500 nM; 18 hr). Error bars show standard deviation from n = 3 replicates. The
dashed red line shows 25.1% Tg activity.
DOI: 10.7554/eLife.15550.003
The following figure supplement is available for figure 1:
Figure supplement 1. DOI: 10.7554/eLife.15550.004
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HEK293T-Rex cells and selected a single clone exhibiting dose-dependent reporter activation upon
treatment with the ER stressors Tg or Tm (Figure 1C,D). This assay was further miniaturized for
1536-well high-throughput screening at the Scripps Research Institute Molecule Screening Center
(SRIMSC) (Supplementary file 1).
We then screened the 644,951-small molecule Scripps Drug Discovery Library (SDDL) at SRIMSC
to identify molecules that activate the ERSE-FLuc reporter. The performance of this assay was consis-
tent across all experimental plates (Z’ = 0.58 ± 0.05) and exhibited a robust signal to noise ratio (sig-
nal/background = 6.21 ± 0.73) (Supplementary file 1). Small molecule activation of ERSE-FLuc was
normalized to Tg (assigned to be 100% activation), allowing comparisons between screening plates.
This screen identified 13,799 molcules that activated the ERSE-FLuc reporter >25.1%. These hits
were then filtered against results from a previous screen of the SDDL to remove 49 small molecules
that activate the cytosolic heat shock response (Calamini et al., 2012). Confirmation screening of
the remaining 13,750 compounds identified 12,376 molcules that activated the ERSE-FLuc reporter
3 standard deviations above the DMSO control (hit cutoff 5.7% activation)–a 90% hit confirmation
(Figure 1E). To decrease the number of compounds for follow-up, we increased the cutoff strin-
gency to that used in the primary screen (25.1% activation), which narrowed the list of ERSE-FLuc
activators to 281 compounds (Figure 1E, Figure 2B—source data). These include the ER stressors
Tg and Tm, which were both present in the SDDL. All 281 confirmed hits were subjected to quality
control at SRIMSC to confirm identity and purity using liquid chromatography/mass spectrometry. A
maximum common substructure search identified 12 chemical substructures that were highly repre-
sented in these 281 ERSE-FLuc activators (Figure 1—figure supplement 1B,C). These include cate-
chols (64/281), anilides (61/281) and benzylidine hydrazines (33/281).
Counterscreening excludes molecules that induce ER stress and/or
globally activate the UPR
We next sought to identify small molecule ER proteostasis regulators that preferentially activate the
ATF6 transcriptional program independent of global ER stress. To remove molecules that induce ER
stress and global UPR activation, the top 281 compounds were counterscreened using an alternative
luciferase reporter, signifying activation of the IRE1/XBP1s arm of the UPR (Figure 1A). This reporter
contains Renilla luciferase (RLuc) expressed out of frame downstream of the XBP1 splice site, pre-
venting RLuc translation in the absence of ER stress (Figure 2A) (Back et al., 2006; Iwawaki et al.,
2004). In response to ER stress-dependent IRE1 activation, the 26-nt XBP1 intron is removed, pro-
ducing a frame shift that allows for RLuc translation and luminescence. Robust dose-dependent acti-
vation of the XBP1-RLuc reporter upon addition of the ER stressors Tg and Tm was confirmed in
HEK293T-Rex cells stably expressing the XBP1-RLuc reporter, producing a Z’ score of 0.75 for Tg
(Figure 2—figure supplement 1A,B).
We compared the activation of this XBP1-RLuc reporter with that observed for the ERSE-FLuc
reporter, both being normalized to the Tg control (defined as 100% activation). Importantly, Tg (1 of
the 281 screening hits) robustly activates both the ERSE-FLuc and XBP1-Rluc reporters, confirming
the ability of this approach to identify global ER stressors (Figure 2B). In contrast, the majority of
molecules identified in the primary screen (200/281) activate the ERSE-FLuc reporter >2-fold better
than the XBP1s-Rluc reporter (Figure 2B). This suggests that small molecules identified from the
HTS preferentially activate the ATF6 transcriptional program independent of ER stress and/or global
UPR activation.
Transcriptional profiling identifies molecules that preferentially activate
the ATF6 program
As a final filter, we performed multiplex gene expression (MGE) profiling in HEK293T-Rex cells
treated with the 281 hits to directly monitor transcriptional changes and identify compounds that
preferentially active the ATF6 transcriptional program (Figure 1A). While the ATF6 and XBP1s lucif-
erase reporter were indispensible for initial high-throughput screening, we wanted to ensure that
any further prioritization was based on a comprehensive picture of the transcriptional remodeling
induced by the compounds. For instance, we wanted to make certain that the compounds induce
multiple ATF6 targets in addition to BiP, as well as monitor that no other stress-responsive signaling
pathways are affected. For this approach, we defined 5–6 target genes that were previously
Plate et al. eLife 2016;5:e15550. DOI: 10.7554/eLife.15550 5 of 27
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identified as selective targets of the ATF6, XBP1s or PERK signaling pathway (Lu et al., 2004;
Shoulders et al., 2013), as well as genes downstream of other stress responsive signaling pathways,
including the heat shock response (HSR), the oxidative stress response (Nrf2), and inflammatory sig-
naling (NFkB) (see Figure 2C—source data 2 for a complete list of genes). The MGE analysis quanti-
fies mRNA levels of these target genes in HEK293T-Rex cells treated with our prioritized 281 ER
proteostasis regulators. This provides a medium-throughout approach to define transcriptional
changes induced by our screening hits.
We performed hierarchical clustering of the 281 screening hits based on the MGE data
(Figure 2C). This showed that compounds grouped into three distinct transcriptional profiles: 1)
global UPR activators that activate ATF6, XBP1s and PERK target genes (green), 2) preferential acti-
vators of ATF6 targets (pink), and 3) compounds with weak to no transcriptional effect. Apart from
Figure 2. Counter-screening and transcriptional profiling identifies preferential activators of the ATF6 transcriptional program. (A) Schematic of the
XBP1-RLuc splicing reporter used to monitor activation of the IRE1/XBP1s arm of the UPR in HEK293T-Rex cells treated with small molecule ER
proteostasis regulators. (B) Plot of ERSE-FLuc activation and XBP1-RLuc activation for the top 281 small molecule ER proteostasis regulators (6.8 mM; 18
hr) in HEK293T-Rex cells stably expressing ERSE-FLuc or XBP1-RLuc. Activation for each axis is shown as the percent signal relative to Tg treatment (500
nM; 18 hr). Prioritized ER proteostasis regulators described in Table 1 are shown in red. Error bars show standard deviation for n = 3. (C) Heat map of
multiplex gene expression (MGE) profiling for the top 281 ER proteostasis regulator compounds. HEK293T-Rex cells were incubated with 10 mM of each
proteostasis regulator for 6 hr then cells were lysed and MGE profiling was performed. Genes probed constitute transcriptional targets preferentially
induced by the ATF6, XBP1s or PERK arms of the UPR or other stress-responsive signaling pathways, as indicated. Heat map is shown with compounds
clustered according to their activity. The green section represents global ER stressors while the pink sections represent molecules that preferentially
activate the ATF6 transcriptional program. Prioritized ER proteostasis regulators identified in Table 1 are highlighted.
DOI: 10.7554/eLife.15550.005
The following source data and figure supplement are available for figure 2:
2–Source data 1. Excel spreadsheet showing the structure,% activation ERSE-FLuc, and% activation XBP1-RLuc for the top 281 compounds identified
through primary HTS screening and confirmation screening.
DOI: 10.7554/eLife.15550.006
2–Source data 2. Excel spreadsheet showing the Multiplex Gene Expression (MGE) expression data used to prepare Figure 2C and Figure 2—figure
supplement 1C.
DOI: 10.7554/eLife.15550.007
Figure supplement 1. DOI: 10.7554/eLife.15550.008
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the UPR, no compounds significantly induced gene targets regulated by other stress-responsive sig-
naling pathways (Figure 2C). In order to compare the relative induction of UPR-associated transcrip-
tional programs activated downstream of ATF6, IRE1/XBP1s and PERK, we normalized transcript
changes to that observed in Tg-treated cells (Figure 2—figure supplement 1C). This allows direct
comparison of transcriptional reprogramming across the three arms of the UPR. Overall, eighteen
molecules, including the known ER stressors Tg and Tm, were identified to induce genes regulated
by all three arms of the UPR, indicating that these molecules induce ER stress and/or global UPR
activation (Figure 2C). In contrast, 79 compounds exhibited preferential activation of genes regu-
lated in the ATF6 transcriptional program, relative to IRE1/XBP1s and PERK.
We prioritized 8 compounds for further characterization (Table 1 — highlightedin Figure 2C). At
this prioritization stage, we primarily focused on the MGE data and less emphasis was placed on the
ATF6 or XBP1s luciferase reporter activation, as the MGE results provided richer information. The
prioritized compounds were selected based on their ability to preferentially activate the ATF6 tran-
scriptional program with varying magnitude according to the MGE analysis (Figure 2C). Further-
more, we focused on compounds containing a 2-amino-p-cresol moiety (cluster F, Figure 1—figure
supplement 1B–C), as these compounds were enriched within our top 79 preferential activators of
the ATF6 transcriptional program (Figure 2C), but we ensured that other representatives of diverse
structural classes were included. Only catechols (cluster A; Figure 1—figure supplement 1B–C)
were mostly excluded, as these are known to be associated with adverse pharmacology (Baell and
Holloway, 2010).
The toxicity of these 8 prioritized molecules was measured in HEK293T-Rex cells. The compounds
demonstrated maximum toxicity of <10–43% that of doxorubicin, with all of them exhibiting a cyto-
toxic concentration 50% (CC50) of >17 mM (the highest tested concentration) (Supplementary file
2). These results suggest that our three-tiered screening strategy (Figure 1A) allowed identification
of generally non-toxic small molecule ER proteostasis regulators that preferentially activate the ATF6
transcriptional program.
mRNA-Seq and quantitative proteomics define the small molecule-
mediated ER PN reprogramming
Comprehensive transcriptome analysis in HEK293T-Rex cells was employed to further validate the
capacity of three prioritized small molecule ER proteostasis regulators — 132, 147, and 263 — to
preferentially activate the ATF6 transcriptional program. These molecules were selected because
they were structurally diverse and exhibited variable levels of ATF6 activation (measured by reporter
assays and MGE) (Table 1, Figure 2C). As a global UPR activation control, mRNA-seq analysis was
also performed on HEK293T-Rex cells treated with Tg.
Comprehensive transcriptome analysis reveals that 132, 147, and 263 preferentially induce UPR-
regulated genes involved in ER PN maintenance such as BiP, GRP94 and SEL1L (Figure 3—figure
supplement 1A–C, red). Compound 132 induced the most robust induction of these genes, relative
to 147 and 263, consistent with the levels of ERSE-FLuc activation afforded by these molecules
(Table 1). Importantly, these small molecules induced three genes that were not upregulated by Tg-
dependent global UPR activation — HSPA1A, HSPA1B, and HMOX1 (Figure 3—figure supplement
1D–F). HSPA1A and HSPA1B are transcriptional targets of the heat-shock response (HSR)-associated
transcription factor HSF1 (Ryno et al., 2014)and HMOX1 is a transcriptional target of the oxidative
stress response (Yang et al., 2015). Comparing the transcriptional profile previously observed for
HSF1 activation (Ryno et al., 2014) to that observed for 132, 147, and 263 showed no significant
correlation, indicating that these molecules do not induce the HSR (Figure 3—figure supplement
1G–J). Similarly, we did not observe increased expression of oxidative stress markers, indicating that
these molecules do not globally activate the oxidative stress response (Figure 3—figure supple-
ment 1K). These results confirm that our molecules selectively induce UPR-regulated ER proteostasis
genes independent of other stress-responsive signaling pathways.
The ability of 132, 147, and 263 to preferentially activate transcriptional programs induced down-
stream of the ATF6, IRE1/XBP1s, and PERK arms of the UPR was next assessed from the mRNA-seq
data. For this analysis, we defined genesets of >15 UPR target genes activated downstream of each
of these three UPR signaling pathways. Previously published transcriptional profiles of chemical
genetic activation of XBP1s, ATF6 or PERK defined these genesets (Lu et al., 2004;
Shoulders et al., 2013). The induction of the selected genes by 132, 147, and 263 was then
Plate et al. eLife 2016;5:e15550. DOI: 10.7554/eLife.15550 7 of 27
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Table 1. Prioritized ER proteostasis regulators
Name Structure MW
Polar Surface
Area AlogP
Structural moieties
(Figure 1 –
supplement 1B–C)
%
ERSE
-FLuc
activation*
%
XBP1
-RLuc
activation* Promiscuity**
5 271.2 41.13 2.62 - 60.9 ± 6.0 9.1 ± 0.7 1 out of 31
132 283.3 58.56 3.27 F 140.1 ± 17.4 10.3 ± 7.9 2 out of 32
145 260.3 75.36 3.01 F, H 83.4 ± 6.3 24.5 ± 4.7 1 out of 31
147 255.3 49.33 3.35 B, F 63.2 ± 0.6 17.5 ± 1.9 1 out of 32
148 322.3 149.12 2.00 B, F 52.5 ± 14.3 16.6 ± 2.4 3 out of 31
Table 1 continued on next page
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normalized to that observed with Tg, allowing direct comparisons across the three genesets (Fig-
ure 3—source data). The ability of this approach to define preferential ER proteostasis remodeling
was confirmed by demonstrating that chemical genetic ATF6 activation in HEK293DAX cells selec-
tively induces the ATF6 transcriptional program (Figure 3A,B).
Compound 132 significantly activates the ATF6 transcriptional program (75% relative to Tg), but
also robustly induces expression of IRE1/XBP1s and PERK genesets (Figure 3A,C). While modest
preferential activation of the ATF6 transcriptional program is observed, this indicates that 132 is a
global UPR activator. In contrast, compound 147 and to a lesser extent 263 show preferential activa-
tion of the ATF6 transcriptional program relative to IRE1/XBP1s and PERK, albeit to lower levels
showing 45% and 50% activation relative to Tg, respectively (Figure 3A,D,E).
Reprogramming of the ER PN was next monitored using quantitative proteomics in HEK293T-Rex
cells treated with 132, 147 or 263. Protein level changes induced by the addition of these small mol-
ecules correlated with transcript changes observed by mRNA-seq (Figure 3—figure supplement
2A–C). Furthermore, the extent of protein expression changes followed the same trend as the tran-
script changes: induction was highest with compound 132, relative to 263 and 147. We further con-
firmed this trend by quantitative immunoblotting monitoring the expression of several proteins
regulated by the ATF6 transcriptional program (Figure 3—figure supplement 2D). Applying an
analogous geneset analysis to that described above showed that 132 increased levels of proteins
regulated downstream of ATF6, IRE1/XBP1s and PERK to similar extents, further confirming that 132
Table 1 continued
Name Structure MW
Polar Surface
Area AlogP
Structural moieties
(Figure 1 –
supplement 1B–C)
%
ERSE
-FLuc
activation*
%
XBP1
-RLuc
activation* Promiscuity**
238 314.7 69.64 2.94 B, L 68.2 ± 5.7 61.1 ± 0.1.5 2 out of 31
258 393.2 91.15 3.76 C, D 28.6 ± 6.1 32.6 ± 1.0 1 out of 31
263 257.2 90.44 3.10 C 20.7 ± 2.3 2.4 ± 1.0 1 out of 31
*% Tg activation from triplicate confirmation screen at 6.8 mM
** Number of screening assays in which the compound was found active
DOI: 10.7554/eLife.15550.009
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Figure 3. Small molecule ER proteostasis regulators preferentially activate the ATF6 transcriptional program. (A) Heat map showing the upregulation of
ATF6 (blue), XBP1s (red) or PERK (green) target genes in the mRNA-Seq analysis of HEK293T-Rex cells treated with Tg (500 nM), 132 (10 mM), 147 (10
Figure 3 continued on next page
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is a global UPR activator (Figure 3F). However, 147 and 263 preferentially increased levels of pro-
teins regulated by the ATF6 transcriptional program, further confirming that these molecules repro-
gram the ER PN through a mechanism involving preferential activation of this transcriptional
program (Figure 3G,H).
Preferential activation of the ATF6 transcriptional program by 147 and 263 could result from a
mild level of ER stress that should increase upon addition of higher concentrations of these mole-
cules or longer duration of treatment. When monitoring the activation of the ATF6-selective ERSE-
FLuc reporter in HEK293 cells treated with increasing concentrations of 147 and 263 (Figure 3I,J),
neither compound showed significant increases in ERSE-FLuc activation at concentrations >10 mM –
the concentration used for mRNA-seq. Similarly, increasing the concentration of these molecules did
not significantly increase activation of the IRE1/XBP1s-selective XBP1-RLuc reporter. Furthermore,
we observe a maximal BiP induction at 6 hr in cells treated with 147 or 263 over a 24 hr time course
and no time-dependent increases in expression of the XBP1s target Sec24D (Figure 3—figure sup-
plement 2E–F). These results indicate that increasing the concentration or duration of treatment
with small molecule ER proteostasis regulators does not alter their preferential activation of the
ATF6 transcriptional program, suggesting that the compounds do not function by inducing a mild
level of ER stress.
Small molecule activation of the ATF6 transcriptional program involves
processing of endogenous ATF6
We next evaluated whether the preferential activation of the ATF6 transcriptional program afforded
by our small molecules require endogenous ATF6. Expression of the ATF6 target gene BiP was mea-
sured in ATF6+/+ mouse embryonic fibroblast (MEF) cells treated with the top 8 prioritized small
molecule ER proteostasis regulators shown in Table 1. All of these molecules induced BiP expression
in these cells, albeit to varying extents (Figure 4A). In contrast, BiP induction was significantly inhib-
ited in the ATF6-/- MEFs, showing that small molecule-dependent upregulation of a gene included in
the ATF6 transcriptional program requires endogenous ATF6. Importantly, we did not observe sig-
nificant levels of XBP1 splicing or eIF2a phosphorylation in cells treated with the ER proteostasis reg-
ulators, indicating that these molecules do not significantly activate the IRE1/XBP1s or PERK arms of
the UPR (Figure 4B,C).
Figure 3 continued
mM) or 263 (10 mM). Genes used in this analysis were selected from published reports indicating their selectivity for ATF6, XBP1s or PERK (Lu et al.,
2004; Shoulders et al., 2013). The induction of each gene was normalized to the respective induction observed with the global UPR activator Tg and
reported as% Tg induction. The expression of these target genes in the mRNA-Seq analysis of TMP-dependent DHFR-ATF6 activation in HEK293DAX
cells is also shown. The data used to prepare this heat map is included in Table S4. (B–E) Box plots showing the relative activation of ATF6, XBP1s, and
PERK genesets in HEK293DAX cells following TMP-dependent DHFR-ATF6 activation (B) or HEK293T-Rex cells treated with 132(C), 147(D) or 263 (E) from
the data shown in Figure 3A. Differences in activation of the ATF6 geneset relative to the XBP1s or PERK genesets were confirmed by one-way ANOVA
and the p-values of unpaired t-tests are shown. (F–H) Boxplots comparing the average fold change at the protein levels of ATF6, XBP1s and PERK
target sets in HEK293T-Rex cells treated with 10 mM 132 (F), 147(G), or 263 (H) for 16 hr as observed in the proteomics analysis. The protein sets used
here are the same as the genesets for the analysis of the RNA-Seq data (A–E). Differences in activation of the ATF6 target protein set relative to the
XBP1s or PERK target protein sets were confirmed by one-way ANOVA and the p-values of unpaired t-tests are shown. The data used to prepare these
graphs can be found in Table S5. (I–J) Plot showing the relative activation of the ERSE-FLuc (blue) and XBP1-RLuc (red) reporters in HEK293T-Rex cells
treated with the indicated concentration of 147 (I) or 263 (J) for 15 hr. Error bars represent standard error for n = 3 replicates.
DOI: 10.7554/eLife.15550.010
The following source data and figure supplements are available for figure 3:
Source data 1. Excel spreadsheet containing the RNAseq and proteomic geneset data used to prepare Figure 3A–H.
DOI: 10.7554/eLife.15550.011
Figure supplement 1. DOI: 10.7554/eLife.15550.012
Figure supplement 1—source data 1. Excel spreadsheet describing the RNA-seq data used to prepare Figure 3—figure supplement 1A–K.
DOI: 10.7554/eLife.15550.013
Figure supplement 2. DOI: 10.7554/eLife.15550.014
Figure supplement 2—source data 2. Excel spreadsheet describing the whole cell proteomic data used to prepare Figure 3—figure supplement
2A–C.
DOI: 10.7554/eLife.15550.015
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ATF6 activation involves trafficking of the full-length ATF6 protein to the Golgi. ATF6 is then
processed by Site-1 and Site-2 proteases (S1P/S2P) to release the active cytosolic bZIP transcription
factor, facilitating nuclear localization (Ye et al., 2000). To evaluate the influence of the 8 ER proteo-
stasis regulators on ATF6 processing, we measured ATF6 nuclear translocation using a fluorescence-
based high-content imaging assay that quantifies nuclear-localized ATF6-GFP relative to ER-localized
Figure 4. ER proteostasis regulators depend on endogenous ATF6 activation. (A) BIP mRNA measured by qPCR in ATF6+/+ and ATF6-/- MEFs treated
with the indicated small molecule ER proteostasis regulators (10 mM; 6 hr). Error bars show standard error for n > 3. *p<0.05; **p<0.01; ***p<0.001. (B)
Gel showing XBP1 splicing in HEK293T cells measured by RT-PCR. RNA was extracted from cells treated with global ER stressors Tg (500 nM) or
tunicamycin (Tm; 1 mg/mL) or 10 mM of the indicated small molecule ER proteostasis regulator for 3 hr. The small molecule BIX is included as a control.
After generation of cDNA, primers flanking the XBP1 splicing site were used to amplify the longer unspliced (XBP1u) or 26-nt shorter spliced (XBP1s)
segment. (C) Immunoblot showing eIF2a phosphorylation in HEK293T cells treated with Tg (500 nM) or 10 mM of the indicated small molecule ER
proteostasis regulator for the indicated time. (D) Activation of ATF6 as measured by nuclear localization of GFP-ATF6. U2OS-GFP-ATF6 cells were
treated with the top 8 small molecule ER proteostasis regulators (10 mM; 5 hr) or Tg (100 nM; 5 hr) and subcellular localization of GFP was assessed by
confocal microscopy (representative images are shown in Figure 4—figure supplement 1A). The nuclear:ER ratio of GFP signal corresponding to
activation of GFP-ATF6 was calculated by comparing vehicle to Tg treatment. Error bars show standard error for n = 3 replicates. Dotted line shows
mean plus three standard deviations from vehicle treated controls (28.65%). ***p<0.001 using one way ANOVA followed by Tukey’s Multiple
comparison test (compared to vehicle). (E) Plot showing ERSE-FLuc activation in HEK293T-Rex cells treated with the top 8 small molecule ER
proteostasis regulators (10 mM; 18 hr) in the presence (red bars) or absence (grey bars) of the S1P inhibitor PF-429242 (10 mM; 18 hr). Cells treated with
Tg (500 nM; 18 hr) are shown as a control. Error bars show standard error for n = 3. ***p<0.001.
DOI: 10.7554/eLife.15550.016
The following figure supplement is available for figure 4:
Figure supplement 1. DOI: 10.7554/eLife.15550.017
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ATF6-GFP. Treatment with small molecules 132 and 263 increased the nuclear fraction of ATF6-GFP,
reflecting increased ATF6 processing (Figure 4D – figure supplement 1A). Compound 132 and 263
treatment also led to increased accumulation of the 50 kDa ATF6 fragment, resulting from S1P/S2P
proteolysis in the Golgi, as shown by immunoblotting (Figure 4—figure supplement 1B). Other
molecules, including 147, did not significantly increase ATF6-GFP nuclear localization or accumula-
tion of the 50 kDa ATF6 fragment, although it cannot be excluded that they also induce ATF6 proc-
essing, albeit to a lower extent that falls outside the dynamic range or sensitivity of these assays.
To more sensitively evaluate the involvement of ATF6 proteolytic processing in small molecule-
dependent activation of the ATF6 transcriptional program, we utilized the S1P inhibitor PF-429242,
which prevents Tg-mediated ERSE-FLuc activation (Figure 4E) (Hay et al., 2007). PF-429242 also
inhibited the activation of ERSE-FLuc in cells treated with all 8 ER proteostasis regulators
(Figure 4E), reflecting the dependence of our small molecules on S1P proteolysis for ATF6 activa-
tion. Collectively, the ATF6 knockout, nuclear localization and S1P inhibition results indicate that the
small molecule ER proteostasis regulators activate the ATF6 transcriptional program through a
mechanism involving S1P-dependent processing of endogenous ATF6.
ER proteostasis regulators selectively reduce secretion of
amyloidogenic TTR from liver-derived HepG2 cells
ER reprogramming afforded by stress-independent chemical genetic ATF6 activation selectively
reduces secretion of destabilized, amyloidogenic TTR variants from liver-derived HepG2 cells
(Chen et al., 2014; Shoulders et al., 2013). Thus, small molecule ER proteostasis regulators that
preferentially activate the ATF6 transcriptional program, such as 147 and 263, should similarly
reduce secretion of destabilized, amyloidogenic TTR from HepG2 cells. We confirmed that 147 and
263 induced expression of the ATF6-target gene BiP in HepG2 cells by qPCR (Figure 5—figure sup-
plement 1A). We also showed that the treatment dose of these small molecules (10 mM) does not
influence HepG2 viability, although higher concentrations (100 mM) do reduce viability (Figure 5—
figure supplement 1B).
We used [35S] metabolic labeling to quantify secretion of FLAG-tagged destabilized A25T TTR
(FTTTRA25T) or FLAG-tagged wild-type TTR (FTTTRWT) from HepG2 cells stably expressing DHFR-
ATF6 (HepG2ATF6). Cells were pretreated with the global ER stressor Tg or small molecule ER pro-
teostasis regulators 147 or 263 (Figure 5A). Pretreatment with Tg reduced secretion of both
FTTTRA25T and FTTTRWT (Figure 5B—figure supplement 1C). However, pretreatment with 147 and
263 reduced FTTTRA25T secretion by 45%, but did not significantly influence secretion of FTTTRWT
(Figure 5B—figure supplement 1C). The reduction in FTTTRA25T secretion induced by these mole-
cules correlates with increased degradation of FTTTRA25T (Figure 5C). Notably, the selective reduc-
tion in secretion and increase in degradation for FTTTRA25T induced by 147 and 263 is strictly
analogous to that observed after chemical genetic ATF6 activation in these cells (Figure 5—figure
supplement 1D,E) (Chen et al., 2014). This indicates that these small molecule ER proteostasis reg-
ulators phenocopy the capacity of chemical genetic ATF6 activation to selectively reduce secretion
of destabilized, amyloidogenic TTR variants relative to the wild-type protein.
We next evaluated whether pretreatment by 147 and 263 influences secretion of the endogenous
secretory proteome from HepG2ATF6 cells using a [35S] metabolic labeling approach (Figure 5—fig-
ure supplement 1F) (Chen et al., 2014; Shoulders et al., 2013). Treatment with the ER stressor Tg
significantly reduced the recovery of [35S] labeled proteins in conditioned media, consistent with the
ability of ER stress to induce translational attenuation and globally disrupt protein secretion
(Figure 5D—figure supplement 1F). However, chemical genetic ATF6 activation, or pharmacologic
activation of the ATF6 transcriptional program through addition of compound 147 or 263, did not
influence the levels of [35S] labeled proteins in media, demonstrating that preferential ATF6 activa-
tion does not globally disrupt secretion of the endogenous proteome.
ER proteostasis regulators decrease secretion and extracellular
aggregation of an amyloidogenic light chain
We next tested whether the ER proteostasis regulators reduce the secretion of a destabilized, amy-
loidogenic immunoglobulin LC (ALLC) that undergoes proteotoxic extracellular aggregation in asso-
ciation with AL (Arendt et al., 2008). Chemical genetic ATF6 activation reduces secretion and
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extracellular aggregation of ALLC without notably affecting secretion of a stable, non-amyloidogenic
LC (Cooley et al., 2014). We evaluated whether our prioritized ER proteostasis regulators similarly
reduce secretion of the same ALLC from an AL patient-derived plasma cell line (ALMC-2)
(Arendt et al., 2008). Compound 147 induced expression of the ATF6 target gene BiP in ALMC-2
cells but unexpectedly, 263 did not (Figure 6A). Treatment with compound 147 reduced ALLC
secretion >50% from ALMC-2 cells, as measured by an ELISA assay while 263 did not significantly
influence ALLC secretion (Figure 6B). Dose-dependent treatment with 147 measuring ALLC
Figure 5. Small molecule ER proteostasis regulators reduce secretion of destabilized amyloidogenic TTRA25T from HepG2 cells. (A) Representative
autoradiogram of [35S]-labeled FTTTRWT or FTTTRA25T in the lysate (Lys) and media (Med) of HepG2ATF6 cells pretreated for 15 hr with 10 mM small
molecule 147 or 263, or 1 mM Tg, incubated with [35S] for 30 min, and then incubated in fresh non-radioactive media for 0 or 4 hr. The experimental
paradigm is shown above. (B) Quantification of the normalized fraction FTTTRWT (open bars) or FTTTRA25T (colored bars) secreted following a 4 hr chase
in HepG2ATF6 cells pretreated for 15 hr with Tg (1 mM; blue) or 10 mM small molecule 147 (red) or 263 (green). Fraction secreted was calculated using
the equation: fraction secreted = [extracellular [35S]-TTR signal at t / (extracellular [35S]-TTR signal at t=0 + intracellular [35S]-TTR signal at t=0)].
Normalized fraction secreted was calculated relative to vehicle-treated controls using the equation: normalized fraction secreted = fraction secreted
treatment / fraction secreted vehicle. Representative autoradiograms are shown in Figure 5A. Raw fraction secreted is shown in figure supplement 1C.
Error bars show standard error for n = 4 replicates; *p<0.05, ***p<0.001. (C) Quantification of the normalized fraction FTTTRWT (open bars) or FTTTRA25T
(colored bars) remaining (lysate + media) following a 4 hr chase in HepG2ATF6 cells pretreated for 15 hr with Tg (1 mM; blue) or 10 mM small molecule
147 (red) or 263 (green). Fraction remaining was calculated using the equation: [(extracellular [35S]-TTR signal at t + intracellular [35S]-TTR signal at t) /
(extracellular [35S]-TTR signal at t=0 + intracellular [35S]-TTR signal at t=0)]. Normalized fraction remaining was calculated relative to vehicle-treated
controls using the equation: normalized fraction remaining = fraction remaining treatment / fraction remaining vehicle. Representative autoradiograms
are shown in Figure 5A. Error bars show standard error for n = 4 replicates; *p<0.05, **p<0.01, ***p<0.001. (D) Quantification for normalized total [35S]-
labeled proteins secreted from HepG2ATF6 cells following 15 hr pretreatment with 1 mM Tg (blue), TMP (10 mM)-dependent DHFR-ATF6 activation
(purple), or 10 mM small molecule ER proteostasis regulators 147 (red) or 263 (green). The experimental protocol and a representative autoradiogram
for this experiment is shown in figure supplement 1G. The recovery of [35S] labeled proteins is normalized to the vehicle-treated control. Error bars
show standard error for n = 4 replicates. ***indicates p<0.001.
DOI: 10.7554/eLife.15550.018
The following figure supplement is available for figure 5:
Figure supplement 1. DOI: 10.7554/eLife.15550.019
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Figure 6. Small molecule ER proteostasis regulators reduce secretion of destabilized, amyloidogenic
immunoglobulin light chains from AL patient-derived plasma cells. (A) qPCR analysis of BiP expression in ALMC-2
cells treated for 6 hr with 10 mM of the indicated small molecule ER proteostasis regulators. Error bars show
standard error for n = 3 replicates. *p< 0.05. (B) Graph showing relative media levels of ALLC measured by ELISA
(red) and cellular viability (blue) of ALMC-2 cells pretreated with 10 mM of the indicated small molecule ER
proteostasis regulators. Cells treated with 500 nM Tg are shown as a control. Error bars show standard error for n
> 6 replicates. ***p<0.001. (C) Dose response curves of reduction in ALLC secretion from ALMC-2 cells after 147
treatment. ALMC-2 cells were pretreated for 15 hr, and subsequently the media was exchanged and conditioned
on the cells for 2 hr. Secreted ALLC concentration was measured by ELISA using an antibody directed against free
l LC (red). Cell viability was measured by CellTiter-Glo (blue). Error bars represent standard error from n = 3
replicates. Data was fit to four parameter logistic functions to calculate EC50 values. (D) Graph showing relative
media levels of IgG measured by ELISA (red) and cellular viability (blue) of KAS-6/1 cells treated with 10 mM of the
indicated small molecule ER proteostasis regulators. Cells treated with 500 nM Tg are shown as a control. Error
bars show standard error for n = 3 replicates. **p<0.01, ***p<0.001. (E) Quantification of ALLC
immunopurifications from ALMC-2 cells after treatment with the indicated ER proteostasis regulator (10 mM; 16 h)
and in situ cross-linking. The relative recovery of GRP94 and BiP in each sample normalized to the recovered ALLC
is shown. A representative immunoblot is shown in figure supplement 1D. Error bars show standard error for n = 4
replicates. *p<0.05; **p<0.01. (F) Blue Native (BN)-PAGE/Immunoblot of conditioned media prepared on ALMC-2
cells pretreated with the indicated ER proteostasis regulator (10 mM; 16 hr). After pretreatment, media were
exchanged and the volume adjusted to account for decreases in cell viability with several compounds. After
conditioning for 8 hr, the media were collected and then heated to 55˚C for 8 hr to induce ALLC aggregation. An
Figure 6 continued on next page
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secretion afforded an EC50 value of 1.1 mM (Figure 6C). The attenuation in ALLC secretion saturated
above 10 mM, producing a similar dose-response curve to 147-dependent ATF6 reporter activation
(Figure 3I). Conversely, compared to the reduction in ALLC secretion, these molecules only mini-
mally affected the secretion of an energetically normal, fully assembled IgG from a control KAS-6/1
plasma cell line isolated from a multiple myeloma patient that did not present with AL (Figure 6D)
(Westendorf et al., 1996). These data indicate that small molecule ER proteostasis regulators that
preferentially activate the ATF6 transcriptional program, e.g. 147, selectively reduce secretion of
destabilized, amyloidogenic LCs, but not IgGs. Additional ER proteostasis regulator compounds
tested also reduced secretion of amyloidogenic ALLC from ALMC-2 cells, while only minimally affect-
ing IgG secretion from KAS-6/1 cells (Figure 6)
Tg treatment reduced viability of ALMC-2 and KAS-6/1 cells (Figure 6B,D). Thus, reductions of
ALLC secretion afforded by these treatments in part reflect cell death. However, the preferential
activator of the ATF6 transcriptional program, 147, only minimally influenced the viability of ALMC-2
or KAS-6/1 cells (Figure 6B–D), suggesting that the reductions in ALLC secretion afforded by this
molecule involve reprogramming of the ER PN. Consistent with this prediction, small molecule-
dependent reductions in ALLC secretion from ALMC-2 cells strongly correlate with BiP induction in
these cells (Figure 6—figure supplement 1C). Furthermore, immunopurification of ALLC from
ALMC-2 cells pretreated with 147 and subjected to in situ crosslinking showed increased interactions
between ALLC and the ATF6-regulated chaperones BiP and GRP94 (Figure 6E—figure supplement
1D). However, pretreatment with 263, which did not induce BiP in ALMC-2 cells, did not increase
the co-isolation of these chaperones. These results suggest that pharmacologic reductions in ALLC
secretion are linked to reprogramming of the ER proteostasis environment.
We previously showed that chemical genetic ATF6 activation reduces ALLC secretion through a
mechanism involving prolonged ER retention (Cooley et al., 2014). In contrast, genetic XBP1s acti-
vation reduces ALLC secretion by increasing its degradation. Therefore, evaluating the mechanism
by which the small molecules reduce ALLC secretion provides insight into the specific type of ER
reprogramming involved in this process. A cycloheximide chase assay demonstrated that pretreat-
ment with 147 reduced ALLC secretion by 30% through a mechanism involving increased ER reten-
tion (Figure 6—figure supplement 1E–G). This indicates that 147 reduces secretion of ALLC
through a mechanism similar or identical to that previously observed with chemical genetic ATF6
activation.
Finally, we evaluated whether pharmacologic ATF6-mediated reductions in ALLC secretion atten-
uated extracellular ALLC aggregation. Soluble ALLC aggregates were quantified in conditioned
media from ALMC-2 cells after heating to 55˚C for 8 hr using Blue-Native PAGE and immunoblotting
(Cooley et al., 2014). Total ALLC protein levels were also determined by SDS-PAGE and immuno-
blotting. Treatment with 147 decreased extracellular ALLC aggregates by >50% (Figure 6F—figure
supplement 6H). Similar reduction in aggregation was observed for additional ER proteostasis regu-
lators tested that lowered ALLC secretion (Figure 6F—figure supplement 6H,I). This indicates that
the reduction in ALLC secretion afforded by our ER proteostasis regulators attenuates extracellular
LC aggregation.
Discussion
Reprogramming of subcellular proteostasis environments through activation of stress-responsive sig-
naling pathways is a promising strategy to restore mutant protein folding or enhance mutant protein
degradation (Calamini and Morimoto, 2012; Chen et al., 2015; Das et al., 2015). Here, we
employed high-throughput screening in combination with medium-throughput transcriptional
Figure 6 continued
SDS-PAGE/immunoblot of the same samples is shown as a control. (G) Quantification of the total (red) and
aggregate (blue) ALLC amounts in the immunoblots as shown in Figure 6—figure supplement 1H. Error bars
show standard error for n > 3 replicates. *p<0.05, **p<0.01, ***p<0.001.
DOI: 10.7554/eLife.15550.020
The following figure supplement is available for figure 6:
Figure supplement 1. DOI: 10.7554/eLife.15550.021
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profiling to identify small molecule ER proteostasis regulators that preferentially activate the ATF6
transcriptional program of the UPR. We show that pharmacologic activation of the ATF6 transcrip-
tional program requires S1P-dependent processing of endogenous ATF6. Furthermore, we show
that our small molecule ER proteostasis regulators phenocopy the capacity of chemical genetic
ATF6 activation to selectively reduce secretion and extracellular aggregation of destabilized amyloi-
dogenic variants of proteins such as TTR and LC. These results reveal a new strategy to identify small
molecules that reprogram the ER PN and correct imbalances in ER function through preferential acti-
vation of a specific sub-UPR transcriptional program.
Our phenotypic screening approach sought to identify small molecule ER proteostasis regulators
that activated the ATF6 transcriptional program, without placing a constraint for the compounds to
act directly on ATF6. Nonetheless, prioritized compounds such as 147 and 263 function through a
mechanism that requires endogenous ATF6. ATF6 is activated through a mechanism distinct to that
utilized by the two other arms of the UPR. In response to ER stress, ATF6 traffics to the Golgi where
it is proteolytically processed by S1P and S2P (Ye et al., 2000). This releases the ATF6 bZIP tran-
scription factor into the cytosol, facilitating its translocation to the nucleus where it promotes induc-
tion of the ATF6 transcriptional program. ATF6 is not known to contain any allosteric small molecule
binding sites. Thus, it is likely that our molecules promote ATF6 activation through interactions with
proteins that regulate its activity such as BiP and the PDIs. Both of these are predicted to be
involved in initiating ATF6 trafficking to the Golgi, although their role in this process remains poorly
defined (Nadanaka et al., 2007; Shen et al., 2002). Our small molecules could also preferentially
induce ATF6 activity by targeting or mimicking metabolites required for activation of this pathway.
Previous work shows that PERK and IRE1 can be activated independent of ATF6 in response to alter-
ations in cellular lipid composition (Volmer et al., 2013) but no such mechanism has been reported
for ATF6 to date.
Interestingly, ER proteostasis regulators identified in our screen appear to preferentially induce
ATF6 activation through distinct mechanisms. This is evident for molecules such as 263, which dem-
onstrates varying levels of BiP induction in distinct cell types (e.g., 263 induces BiP in HEK293T and
HepG2 cells, but not in ALMC-2 cells). This is in contrast to compound 147 that activates the ATF6
pathway in all cell types tested. This capacity to activate ATF6 in a cell type specific fashion could be
harnessed to define the underlying molecular mechanisms involved in ATF6 activation and develop
compounds that induce tissue selective ER PN remodeling. As we continue to optimize the potency
and ATF6 selectivity of these small molecule ER proteostasis regulators, new insights into the molec-
ular pathways that regulate ATF6 activity will likely emerge.
One mechanism by which the ATF6 transcriptional program influences ER function is by increasing
the stringency of ER protein quality control (Chen et al., 2015). Stress-independent ATF6 activation
selectively attenuates the secretion and subsequent proteotoxic aggregation of destabilized, dis-
ease-associated proteins without effecting the secretion of the endogenous proteome (Chen et al.,
2014; Chiang et al., 2012; Cooley et al., 2014; Shoulders et al., 2013; Smith et al., 2011). Our
top small molecule ER proteostasis regulators (e.g., 147) phenocopy the ability of chemical genetic
ATF6 activation to selectively reduce secretion of destabilized, disease-associated variants of amyloi-
dogenic proteins such as TTR and immunoglobulin LC. This suggests that our small molecules could
similarly phenocopy the ATF6-dependent reductions in the trafficking and intracellular aggregation
of destabilized, aggregation-prone proteins associated with other gain-of-toxicity protein misfolding
diseases (e.g., A1AT-Z aggregation in liver disease and rhodopsin aggregation in retinal degenera-
tion (Chiang et al., 2012; Smith et al., 2011)). Thus, small molecule ER proteostasis regulators iden-
tified herein have the potential to broadly ameliorate degenerative diseases associated with
aggregation of secretory proteins.
The long-term consequences of periodic pharmacologic activation of the ATF6 arm of the UPR
are unclear. Mechanism-based toxicity associated with adapting ER proteostasis to ameliorate secre-
tory protein misfolding and/or aggregation is possible. While some small molecule ER proteostasis
regulators identified show mild toxicity, a subset of compounds, especially compounds that prefer-
entially activate the ATF6 transcriptional program (e.g., 147), show no significant toxicity across mul-
tiple cell models. This likely reflects the limited activation of the IRE1/XBP1s and PERK arms of the
UPR afforded by these molecules, minimizing apoptosis signaling induced downstream of these two
UPR signaling pathways (Hetz, 2012; Tabas and Ron, 2011). The moderate levels of ATF6 activation
achieved using our small molecule ER proteostasis regulators likely also minimize pathologic
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imbalances in ER function. It is known that high levels of ATF6 activation induce hepatic steatosis in
zebrafish, whereas lower levels do not (Howarth et al., 2014). Finally, the low molecular weight and
structural simplicity of the small molecules identified by our multi-tiered screening strategy (e.g.,
147) provides a significant amount of chemical space that can be explored through structure-activity
relationships to optimize potency, selectivity and dosing regimens, while minimizing toxicity.
Several of our prioritized molecules include functional groups found in pan-assay interference
compounds (PAINS) (Baell and Walters, 2014), but given that these ER proteostasis regulators
showed activity in multiple complementary screening assays, they are unlikely to act through off-tar-
get pathways. Consistent with this, the molecules depend on ATF6 and its canonical activation path-
way for the induction of ATF6 target genes. Furthermore, the RNA-Seq and proteomics profiling
analysis for 147 and 263 confirmed that these molecules exert very little off-target transcriptome
changes and proteome remodeling apart form preferential ER proteostasis network activation. Both
147 and 263 contain functional groups that after metabolic oxidation to a quinone methide could
modify proteins covalently. This suggests that the covalent modification of ATF6 or a protein
involved in the regulation of ATF6 activity (e.g. BiP or PDIs) (Nadanaka et al., 2007; Shen et al.,
2002) by our small molecules could be involved in the activation mechanism. Future medicinal chem-
istry efforts will focus on exploring the mechanism of action of these compounds and the potential
involvement of covalent protein modification for their activity.
The establishment of ER proteostasis regulators, such as 147, provides a unique opportunity to
define the underlying molecular mechanism(s) of ATF6 activation and to probe the involvement of
ATF6 in regulating ER PN function. These molecules also represent a valuable resource to define the
therapeutic potential of ATF6 transcriptional program activation to correct pathologic imbalances in
ER proteostasis in cellular and animal models of protein aggregation diseases. As we continue to
develop our top small molecule ER proteostasis regulators through medicinal chemistry, we will
establish second generation molecules that optimize ER PN reprogramming to ameliorate patho-
logic imbalances in ER proteostasis associated with diverse protein aggregation diseases such as the
systemic amyloidosis.
Materials and methods
Compounds
All compounds were obtained from the commercial vendors listed in Table S2 and were used with-
out further purification by dissolving in sterile dimethyl sulfoxide (DMSO). The identity of screening
compounds was confirmed by LC-MS analysis and all compounds were shown to be >90% pure
(Table S2).
Plasmids
ERSE-Firefly luciferase reporter was cloned into a vector suitable for mammalian cell selection by
transferring ERSE-FLuc from ERSE-FLuc.pGL3 (Yoshida et al., 1998) into a promotorless pcDNA3.1
vector using Xba1 and Not1 restriction sites to create ERSE.FLuc.pcDNA3.1. XBP1s-Renilla luciferase
was generated from a known XBP1s-GFP reporter (Iwawaki et al., 2004). GFP was exchanged for
Renilla luciferase by the Polymerase Incomplete Primer Extension (PIPE) method (Klock and Lesley,
2009) using the following primers: vector, XBP1s-GFP.pCEFL, CTGAAGAACGAGCAGTAAGTGAG-
CAAGGGCGAGGAG and CGTACACCTTGGAAGCAGATCTTGAATCTGAAGAGTCAATACC; gene,
CMV-Renilla, CGGTATTGACTCTTCAGATTCAAGATCTGCTTCCAAGGTGTACG and CTCCTCGCCC
TTGCTCACTTACTGCTCGTTCTTCAG to create XBP1s-RLuc pCEFL. TTR point mutations were
incorporated into the FLAG2-TTR pcDNA3.1 vector through site-directed mutagenesis
(Shoulders et al., 2013).
Cell culture and transfections
HEK293T-Rex (ATCC), HEK293T (ATCC), HEK293DAX (Shoulders et al., 2013), HepG2 (ATCC),
HepG2ATF6(Chen et al., 2014), and ATF6+/+ MEFs and ATF6-/- MEFs (a kind gift from Randal Kauf-
man’s lab) were cultured in High-Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with glutamine, penicillin/streptomycin and 10% fetal bovine serum. Cells were routinely
tested for mycoplasma every 6 months. No further authentication of cell lines was performed by the
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authors. HEK293 cells containing the ERSE-FLuc or XBP1s-RLuc reporters were created by transfec-
tion with ERSE-FLuc pcDNA3.1 or XBP1s-RLuc pCEFL by calcium phosphate followed by culturing in
geneticin sulfate (G-418, 500 mg/mL, ERSE) or puromycin (20 mg/mL, XPB1s). Creation and mainte-
nance of HEK293DAX cells has been described previously (Shoulders et al., 2013). Creation and
maintenance of HepG2ATF6 has been described previously (Chen et al., 2014). U2OS cells stably
expressing GFP-ATF6 were purchased from Thermo Scientific (084_01) and cultured with 500 mg/mL
G418. Transient transfections of FTTTR variants into HepG2ATF6 cells were performed with Lipofect-
amine 3000 (Life Technologies). ALMC-2 and KAS-6/1 plasma cells (a kind gift from Diane Jelinak’s
laboratory) were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) GlutaMAX (Life Technol-
ogies) supplemented with penicillin/streptomycin, 5% fetal bovine serum and 2 ng/mL interleukin-6
(IL-6), as previously described (Arendt et al., 2008). All cells were cultured under typical tissue cul-
ture conditions (37˚C, 5% CO2).
Reporter assays
96-well, HEK293DAX experiments and S1P inhibition
HEK293T-Rex cells incorporating the ERSE-FLuc reporter and HEK293DAX cells were plated approxi-
mately 20,000 cells/well in flat-bottomed, black 96-well assay plates (Costar, Corning, Inc.) overnight
prior to compound administration. Cells were treated with compounds as described for 12–18 hr
then the plates were equilibrated to room temperature and 50 mL of SteadyLite (PerkinElmer) was
added to each well. Luminescence activity was measured in a Safire II microplate reader with a 1000
ms integration time.
384-well, Tg and Tm dose response in reporter cells
HEK293T-Rex cells incorporating either the ERSE-FLuc or XBP1s-RLuc reporters were plated 20 mL/
well from 250,000 cells/mL in white 384-well plates (Corning). Cell plates were centrifuged for 1 min
at 1000 rpm, then incubated at 37˚C overnight. The following day cells were treated as described
with various concentrations of Thapsigargin or Tunicamycin, incubated for a further 18 hr at 37˚C,
equilibrated to room temperature, then 20 mL of SteadyLite (PerkinElmer) or Renilla-Glo (Promega)
were added to each well. Luminescence activity was measured 10 min after reagent addition with an
EnVision Multilabel Reader (PerkinElmer) using a 100 ms integration time.
1536-well, high-throughput screening
HEK293T-Rex cells incorporating either the ERSE-FLuc or XBP1s-RLuc reporters were collected by
trypsinization and resuspended at a density of 500,000 cells per mL. The assay was started by dis-
pensing 5 mL of cell suspension into each well of white, solid-bottom 1536-well plates using a flying
reagent dispenser (FRD) and placed into an online incubator for 3 hr. Cells were then treated with
34 nL/well of either test compounds to give final concentrations of 6.8 mM, DMSO (Low control, final
concentration 0.68%, 0% activation) or 37 mM of Delta-7 thapsigargin (High control, final concentra-
tion 500 nM, 100% activation). Plates were incubated for 18 hr at 37˚C, removed from the incubator
and equilibrated to room temperature for 10 min. Luciferase activity was detected by addition of
5 mL of ONE-Glo reagent (Promega) to each well. After a 10 min incubation time, light emission was
measured with the ViewLux reader (PerkinElmer). The percent activation of each test compound was
calculated as follows:% Activation = 100*(Test Compound- Median Low Control) / (Median High
Control – Median Low Control).
Multiplex gene expression (MGE) profiling
96-well plates were seeded with HEK293 cells, 20,000 cells/well and incubated at 37˚C overnight.
Cells were treated with compounds in media to give a final concentration of 10 mM and incubated
for 6 hr. Media was removed then cell pellets in the plates were frozen at -80˚C. On day of assay,
cell pellets were thawed, lysed and analyzed for gene expression as previously described
(Calamini et al., 2012). RNA expression changes were log2 transformed and clustering was per-
formed in R using a Euclidean distance function and Ward’s method for hierarchical clustering.
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mRNA-Seq
HEK293T-Rex and HEK293DAX cells in 12-well plates were treated for 6 hr with vehicle, 1 mM Tg,
10 mM TMP (in HEK293DAX), or 10 mM 132, 147 or 263 in biological triplicate at 37˚C. Cells were har-
vested, and RNA was extracted using the RNeasy Mini Kit (Qiagen). Total RNA was quantified using
NanoDrop (ND-1000). Samples were run on the Illumina HiSeq system.
Single end, 100 bp-long reads from RNA-Seq experiments were aligned to the GRCh37.p13
human genome reference assembly using SeqMan NGen 11.2.1 (DNAStar, Inc.). The assembly data
were then imported into ArrayStar with QSeq (DNAStar, Inc.) to quantify the gene expression levels.
The sequence counts were normalized to reads per kilobase per million (RPKM) after filtering out
non-mRNA sequence features. The statistical significance of the difference between the expression
levels of a gene under different conditions was assessed using a Student’s t-test with the Benjamini-
Hochberg multiple testing correction.
Geneset analysis of transcriptional data
ATF6- and XBP1s-selective target genes were identified from transcriptional profiles of HEK293DAX
cells following stress-independent activation of TMP-dependent DHFR-ATF6 and/or tetracycline
inducible XBP1s, as previously described (Shoulders et al., 2013). PERK-selective target genes were
identified from (Lu et al., 2004). These genesets are described in Table S5. Only ATF6-, XBP1s- or
PERK-selective genes induced >1.5 fold in Tg-treated samples were used in this analysis. The log
transformed fold-increase of these target genes in HEK293T-Rex cells treated with the respective ER
proteostasis regulators were then normalized to the log transformed fold increase of these genes
induced by Tg treatment. The plots shown in Figure 3B–E were prepared as box and whisker plots
using Kaleidograph. Differential activation of the ATF6, XBP1s, and PERK genesets was assessed by
one-way ANOVA and significance of pairwise comparison confirmed by unpaired t-test. An analo-
gous strategy was employed to prepare the heat map shown in Figure 2—figure supplement 1C
using transcriptional data from the MGE analysis.
Proteomics by TMT-MuDPIT
HEK293T-Rex cells in 6-well plates were treated for 16 hr with vehicle, or 132, 147 or 263 at 37˚C.
Lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 50 mM Tris
pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS) with fresh protease inhibitor
cocktail (Roche) and centrifuged for 20 min at 10000 x g. Protein concentrations of supernatants
were determined by BCA (Pierce). For each sample, 100 mg of lysate was washed by chloroform/
methanol precipitation. Air-dried pellets were resuspended in 1% RapiGest SF (Waters) and brought
up in 100 mM HEPES (pH 8.0). Proteins were reduced with 5 mM Tris(2-carboxyethyl)phosphine
hydrochloride (Pierce) for 30 min and alkylated with 10 mM iodoacetamide (Sigma) for 30 min at
ambient temperature and protected from light. Proteins were digested for 18 hr at 37˚C with 2 mg
trypsin (Promega). After digestion, 20 mg of peptides from each sample were reacted for 1 hr with
the appropriate TMT-NHS isobaric reagent (Pierce) in 40% (v/v) anhydrous acetonitrile and
quenched with 0.4% NH4HCO3 for 1 hr. Samples with different TMT labels were pooled and acidi-
fied with 5% formic acid. Acetonitrile was evaporated on a SpeedVac and debris was removed by
centrifugation for 30 min at 18,000 x g. MuDPIT microcolumns were prepared as described
(Ryno et al., 2014). LCMS/MS analysis was performed using a Q Exactive mass spectrometer
equipped with an EASY nLC 1000 (Thermo Scientific, San Jose, CA). MuDPIT experiments were per-
formed by 5 min sequential injections of 0, 10, 20, 30, . . ., 100% buffer C (500 mM ammonium ace-
tate in buffer A) and a final step of 90% buffer C / 10% buffer B (20% water, 80% acetonitrile, 0.1%
fomic acid, v/v/v) and each step followed by a gradient from buffer A (95% water, 5% acetonitrile,
0.1% formic acid) to buffer B. Electrospray was performed directly from the analytical column by
applying a voltage of 2.5 kV with an inlet capillary temperature of 275˚C. Data-dependent acquisi-
tion of MS/MS spectra were performed with the following settings: eluted peptides were scanned
from 400 to 1800 m/z with a resolution of 30000 and the mass spectrometer in a data dependent
acquisition mode. The top ten peaks for each full scan were fragmented by HCD using a normalized
collision energy of 30%, a 100 ms activation time, a resolution of 7500, and scanned from 100 to
1800 m/z. Dynamic exclusion parameters were 1 repeat count, 30 ms repeat duration, 500 exclusion
list size, 120 s exclusion duration, and exclusion width between 0.51 and 1.51. Peptide identification
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and protein quantification was performed using the Integrated Proteomics Pipeline Suite (IP2, Inte-
grated Proteomics Applications, Inc.) as described previously (Ryno et al., 2014). The geneset analy-
sis (Figure 3F–H) was performed analogous to the analysis of the RNA-seq data using the same
proteins from the genesets for ATF6, XBP1s and PERK and log transformed fold changes of protein
expression. The plots shown in Figure 3F–H were prepared as box and whisker plots using Kaleido-
graph. Differential activation of the ATF6, XBP1s, and PERK target protein sets was assessed by
one-way ANOVA and significance of pairwise comparison confirmed by unpaired t-test. The compar-
ison of RNA-Seq and proteomics data (Figure 3—figure supplement 2A–C) and the data for the
geneset analysis (Figure 3F–H) are included as Source Data.
Statistical methods
Unless otherwise noted, all p-values were calculated by performing a paired or unpaired (noted) t-
test.
Cytotoxicity Assays
HEK293T-Rex cells incorporating either the ERSE-FLuc or XBP1s-RLuc reporters were collected by
trypsinization and resuspended at a density of 500,000 cells per mL. The assay was started by dis-
pensing 5 mL of cell suspension into each well of white, solid-bottom 1536-well plates using a flying
reagent dispenser (FRD) and placed into an online incubator 3 hr. Cells were then treated for 48 hr
with various concentrations of proteostasis regulator, DMSO (0% toxicity) or 340 mM Doxorubicin as
a positive control (100% toxicity). After 48 hr of incubation, toxicity was determined using an ATP
detection method (CellTiter-Glo, Promega).
HepG2 cells were plated at 5000 cells/well in a translucent, flat-bottomed 96 well plate, and
treated for 48 hr with vehicle, 10 mM Tg or 10 mM ER proteostasis regulator. ALMC-2 or KAS-6/1
cells were plated at 33,000 cells/well in 96-well plates then treated with proteostasis regulators for
16 hr as described. Cell metabolic activity was measured using the CellTiter-Glo assay (Promega),
which reports on intracellular ATP concentration. CellTiter-Glo reagent was added to cell culture
media at a 1:1 ratio and incubated for 2 min on an orbital shaker to induce cell lysis. The plate was
then incubated at room temperature for 10 min to stabilize the luminescent signal and read on a
Tecan F200 Pro microplate reader.
Quantitative RT-PCR
Cells were treated as described at 37˚C, washed with Dulbecco’s phosphate-buffered saline (Gibco),
and then RNA was extracted using the RNeasy Mini Kit (Qiagen). qPCR reactions were performed
on cDNA prepared from 500 ng of total cellular RNA using the QuantiTect Reverse Transcription Kit
(Qiagen). The FastStart Universal SYBR Green Master Mix (Roche), cDNA, and appropriate human
primers (Shoulders et al., 2013) or mouse primers (BiP; gtccaggctggtgtcctctc and gattatcg-
gaagccgtggag) purchased from Integrated DNA Technologies were used for amplifications (45
cycles of 1 min at 95˚C, 10 s at 95˚C, 30 sec at 60˚C) in an ABI 7900HT Fast Real Time PCR machine.
Primer integrity was assessed by a thermal melt to confirm homogeneity and the absence of primer
dimers. Transcripts were normalized to the housekeeping gene Rplp2 and all measurements were
performed in triplicate. Data were analyzed using the RQ Manager and DataAssist 2.0 softwares
(ABI).
XBP1 splicing was assessed by RT-PCR followed by gel electrophoresis on a 3% agarose gel using
the following primers flanking the XBP1 splicing sites: 5’-CCTTGTAGTTGAGAACCAGG-3’, 5’-GAG
TCAATACCGCCAGAATC-3’.
ATF6 nuclear localization
300 mL of 1.375 x 104 U2OS-GFP-ATF6 cells per mL were plated per well in 96 well imaging plate
(ibidi 89626) and sealed with breathable seals (E&K Scientific T896100) two days prior to drug addi-
tion. Immediately prior to addition to cells, compounds were diluted to 6x in media from 500x
DMSO stock and 60 mL 6x was added to cells for 1x final (0.2% DMSO).
After 5 hr, media was removed and cells were fixed in 4% PFA (Electron Microscopy Sciences
15714) in PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2-hexahydrate, pH
6.9) for 15 min at RT. Cells were permeabilized with PHEM-Tx (PHEM containing 0.1% Triton X-100,
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two washes, 5 min at RT), washed twice in PHEM and blocked in PHEM containing 2% normal goat
serum (Jackson Immunoresearch Laboratories 005-000-121) for 1 hr at RT. Primary antibodies were
incubated in blocking solution overnight at 4 degrees. Cells were washed three times in PHEM-Tx
then incubated with secondary antibodies and nuclear stain (DAPI, Molecular Probes D-1306, 5 mg/
ml) in blocking solution for 2 hr at RT protected from light. Cells were washed three times in PHEM-
Tx, then twice in PHEM. Antibodies used were rat anti-GRP94 9G10 (Abcam ab2791), mouse anti-
GFP 3E6 (Invitrogen A11120), anti-rat-Alexa-555 (Invitrogen A21434), and anti-mouse-Alexa-488
(Invitrogen A11029), each at 1:1000 dilution.
Plate was imaged on a spinning disk confocal with Yokogawa CSUX A1 scan head, Andor iXon
EMCCD camera and 20x Plan Apo Objective NA 0.79. Using the mManager high-content screening
plugin ’HCS Site Generator’ (Edelstein et al., 2014) 49 fields per well were acquired for a mean cell
number per well of 368  12.
Images were analyzed using CellProfiler (Carpenter et al., 2006), MATLAB R2014a and Graph-
Pad Prism 5. Masks for the ER and nucleus of each cell were created using the GRP94 and DAPI
staining, respectively. The ratio of the GFP intensity in the nucleus versus the ER was calculated for
each cell and plotted as a histogram per well. A threshold for the minimum ratio of nuclear to ER sig-
nal corresponding to an activated (i.e. nuclear localized ATF6) cell was calculated as the minimum
nuclear: ER ratio greater than 1 where the number of ER stressed cells (Tg) was greater than the cor-
responding unstressed control. Percent activation per well was calculated as the percentage of cells
per well with a nuclear: ER ratio greater than the calculated threshold for that plate. Mean percent
activation per well for a minimum of three replicate wells per treatment was plotted and error bars
are standard error of the mean. Compounds are annotated as hits if they show percent activation
more than three standard deviations away from the mean of vehicle treated control.
[35S] Metabolic labeling experiments
HepG2ATF6 cells plated on poly-D-lysine coated dishes were metabolically labeled in DMEM-Cys/-
Met (CellGro) supplemented with glutamine, penicillin/streptomycin, dialyzed fetal bovine serum,
and EasyTag EXPRESS [35S] Protein Labeling Mix (Perkin Elmer) for 30 min. Cells were washed twice
with complete media and incubated in pre-warmed DMEM for the indicated times. Media or lysates
were harvested at the indicated times. Lysates were prepared in RIPA buffer with fresh protease
inhibitor cocktail (Roche). FLAG-tagged TTR variants were immunopurified using M1 anti-FLAG aga-
rose beads (Sigma-Aldrich) and washed three times with RIPA buffer. The immunoisolates were then
eluted by boiling in Laemmli buffer and separated on SDS-PAGE. For total secreted media, 15 uL ali-
quots from media incubated for 4 hrs on pulsed cells were run on a SDS-PAGE. The gels were then
dried, exposed to phosphorimager plates (GE Healthcare), and imaged with a Typhoon imager.
Band intensities were quantified by densitometry in ImageQuant. Fraction secreted was calculated
using the equation: fraction secreted = [extracellular [35S]-TTR signal at t / (extracellular [35S]-TTR sig-
nal at t=0 + intracellular [35S]-TTR signal at t=0)]. Fraction remaining was calculated using the equa-
tion: [(extracellular [35S]-TTR signal at t + intracellular [35S]-TTR signal at t) / (extracellular [35S]-TTR
signal at t=0 + intracellular [35S]-TTR signal at t=0)].
Immunoblotting, SDS-PAGE and immunoprecipitation
For immunoblotting, cells were lysed in 50 mM Tris buffer, pH 7.5 containing 0.1% TritonX (Fisher
Scientific) and supplemented with protease inhibitor cocktail (Roche). For immunoblots of endoge-
nous ATF6, cells were washed in PBS containing protease inhibitor cocktail and 10 mM MG-132 and
subsequently lysed in 1x Laemmli buffer, supplemented in the same way, by repeating cycles of boil-
ing and vortexing. Protein lysate concentrations were normalized by Bradford (Bio-Rad) or BCA
assay (Thermo). Lysates or media were boiled for 5 min in Laemmli buffer + 100 mM DTT before
loading onto SDS-PAGE gel. Proteins were transferred from gel slabs to nitrocellulose, and the
Odyssey Infrared Imaging System (Li-Cor Biosciences) was used to detect proteins of interest.
For immunoprecipitations, cells were washed with PBS then cross-linked with 0.5 mM Dithiobis
(succinimidiyl propionate) (DSP) for 30 min at room temperature. The reaction was quenched by
addition of 100 mM Tris pH 7.5, then RIPA buffer was added to the cell pellets for lysis. Lysates
were cleared by centrifugation at centrifuged at 10000 x g for 15 min. Proteins were immunopurified
using sheep polyclonal free l LC antibody (Bethyl Laboratories A80-127A) that was covalently
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conjugated to CNBr-activated Sepharose 4B (GE Healthcare). After four washes in RIPA buffer, pro-
teins were eluted by boiling in Laemmli buffer + 100 mM DTT and samples were separated by SDS-
PAGE and transferred to nitrocellulose membranes. Blots were probed with the following primary
antibodies: monoclonal mouse M2 anti-FLAG (1:500, Sigma), polyclonal rabbit anti-TTR (1:1000,
Dako), rabbit polyclonal anti-human lambda light chain (1:1000, Bethyl Laboratories A90-112A),
mouse monoclonal anti-Grp78 (1:500, Santa Cruz Biotechnology sc-166490), rabbit polyclonal anti-
Grp94 (1:1000, GeneTex GTX103203), rabbit polyclonal anti-PDIA4 (1:1000, Protein Tech Group
14712-1-AP), mouse monoclonal anti-ATF6a (1–7) (BioAcademia, 1:1000), rabbit anti-phospho eIF2a
(CellSignaling #9721, 1:500), mouse anti-eIF2a (Abcam ab5369, 1:1000) and mouse monoclonal anti
b-actin (1:10000, Sigma).
Light chain ELISA
ALMC-2 or KAS-6/1 plasma cells were plated 100,000 cells/well in 150 mL of media in 96-well Multi-
ScreenHTS filtration plates (Millipore MSBVS1210). Triplicate wells were treated with DMSO or com-
pounds at the indicated concentrations and incubated for 16 hr. Media was removed by filtration
using a QIAvac 96 vaccuum manifold (Qiagen) and wells were washed two times with 150 mL media.
Wells were then incubated with 150 mL of fresh media for 2 hr and the conditioned media was har-
vested into a 96-well plate using the vacuum manifold. Free LC and IgG concentrations were deter-
mined by ELISA in 96-well plates (Immulon 4HBX, Thermo Scientific). Wells were coated overnight at
37ºC with rabbit anti-human l light chain polyclonal antibody (Bethyl Laboratories, A90-112A) at a
1:1000 dilution or human IgG-heavy and light chain antibody (Bethyl Laboratories, A80-118A) at a
1:2000 dilution in 50 mM sodium carbonate (pH 9.6). In between all incubation steps, the plates
were rinsed extensively with Tris-buffered saline containing 0.05% Tween-20 (TBST). Plates were
blocked with 5% non-fat dry milk in TBST for 1 hr at
37ºC. Media analytes were diluted between 5 – 200 fold in 5% non-fat dry milk in TBST and
100 mL of each sample was added to individual wells. Light chain or IgG standards ranging from 3 –
300 ng/mL were prepared from purified human Bence Jones l light chain or human reference serum
(Bethyl Laboratories, P80-127 and RS10-110). Plates were incubated at 37ºC for 1.5 hr while shaking.
Finally, HRP-conjugated goat anti-human l light chain antibody (Bethyl Laboratories, A80-116P) was
added at a 1:10,000 dilution or HRP-conjugate IgG-Fc fragment cross-adsorbed antibody (Bethyl
Laboratories, A80-304P, 1:30,000 dilution) was added in 5% non-fat dry milk in TBST, followed by a
1.5 hr incubation of the plates at 37ºC. The detection was carried out with 2,2’-azinobis(3-ethylben-
zothiazoline-6-sulfonic acid) (ABTS, 0.18 mg/mL) and 0.03% hydrogen peroxide in 100 mM sodium
citrate pH 4.0. Detection solution (100 mL) was added to each well and the plates were incubated at
room temperature. The absorbance was recorded at 405 nm and the values for the LC standards
were fitted to a 4-parameter logistic function. Light chain or IgG concentrations were averaged from
at least 3 independent replicates under each treatment and then normalized to vehicle conditions.
Conditioned media aggregation and blue-native PAGE
ALMC-2 plasma cells were plated 2 x 106 cells/well in 1 mL of media in 12-well plates. Wells were
treated with DMSO or 10 mL of compounds and incubated for 16 hr. Cells were transferred to micro-
centrifuge tubes and washed two times in media. Small aliquots (10 mL) of cells were removed for a
Cytotoxicity assay as described above. Cells were resuspended in media (1 mL for DMSO treatment)
and the volume was adjusted for each treatment based on cell viability. Cells were conditioned in
the media for 8 hr and then were removed by centrifugation. The media samples were immunopreci-
pitated overnight at 4C with recombinant Protein A – Sepharose 4B resin (Life Technologies) to
remove fully assembled IgGs that interfere with LC aggregate detection. Cleared media samples
were then heated to
55C for 8 hr to induce LC aggregation, added to Blue-Native PAGE loading dye (10% glycerol,
0.5% Coomassie G-250) and then loaded onto 3–12% Bis-Tris gradient gels (Life Technologies). The
cathode buffer contained 50 mM Tricene and 15 mM Bis-Tris, pH 7.0 with 0.02% Coomassie G-250.
The anode buffer contained 50 mM Bis-Tris pH 7.0. The gels were transferred onto PVDF mem-
branes and LC was detected by rabbit anti-human l light chain polyclonal antibody (Bethyl), fol-
lowed by HRP-conjugated secondary antibodies. The blots were imaged using a chemiluminescence
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substrate (Luminata Forte Western Luminescence Substrate, Millipore) and imaged with a ChemiDoc
XRS+ scanner (Biorad).
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